SKIN — The Beauty Health Company

Summary of SkinHealth Systems Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Sales: $64.9 million, down 6.7% year-over-year, within guidance of $63 million to $68 million.
• Adjusted EBITDA: $8.5 million, up 17% year-over-year, exceeding the high end of guidance ($3.5 million to $5.5 million).
• Consumables Revenue: $46.4 million, down 6.1% year-over-year, impacted by the transition to a distributor model in China.
• Delivery Systems Revenue: $18.5 million, down 8.3% year-over-year, with 746 systems placed compared to 862 in Q1 2025.
• Active Installed Base: Grew to 36,400 devices, up 4% year-over-year.
• Adjusted Gross Margin: 72.2%, slightly improved from 71.9% in the prior year.
• Net Loss: Improved to $6.6 million from $10.1 million in the prior year.
• Cash Position: Ended the quarter with $204.4 million in cash and equivalents.

2. Strategic Updates and Business Highlights

• The company rebranded to Skin Health Systems, emphasizing a shift towards a more clinically rigorous and commercially disciplined approach.
• Hydrafacial remains central to the strategy, with plans to enhance the product platform, including the relaunch of Keravive for scalp health.
• New independent directors were added to the Board to support growth.
• The company is focusing on improving commercial execution and sales discipline to enhance conversion rates.

3. Forward Guidance and Outlook

• Revised Full-Year Revenue Outlook: $280 million to $295 million, a reduction of approximately 2.5% from previous guidance due to expected continued softness in capital equipment demand.
• Adjusted EBITDA Guidance: Maintained at $35 million to $45 million, reflecting operational strength.
• Q2 Revenue Expectation: $72 million to $77 million, with adjusted EBITDA of $11 million to $13 million.
• The company anticipates a gradual improvement in performance throughout 2026, with a focus on execution and utilization of the installed base.

4. Bad News, Challenges, or Points of Concern

• Device Placements: Below expectations, attributed to macroeconomic factors, tighter credit conditions, and increased competition.
• Consumables Decline: Primarily affected by the transition to a distributor model in China and timing-related variability in other regions.
• Market Conditions: Continued pressure from competition, particularly from lower-cost alternatives and secondary market devices.
• Execution Risks: The effectiveness of the commercial initiatives and the timing of improvements in device placements and utilization remain uncertain.

5. Notable Q&A Insights

• Competition: Increased competition is noted, particularly from lower-cost alternatives and a broader range of aesthetic treatments. The company aims to differentiate through clinical outcomes rather than price.
• Innovation Focus: Emphasis on restructuring the booster portfolio to enhance clinical outcomes and provider economics. Two new boosters are expected to launch in 2026.
• Cash Flow Management: The company expects modest free cash flow generation in the latter half of the year, with capital expenditures projected at $8 million to $10 million.
• Market Trends: The management believes that while the current year may not see significant growth, 2027 could present opportunities for more consistent growth as initiatives take effect.

Overall, while SkinHealth Systems faces challenges in the short term, particularly in device placements and competitive pressures, the company remains focused on strategic initiatives and operational improvements to drive future growth.